222 related articles for article (PubMed ID: 20464498)
21. Extensive aspartoacylase expression in the rat central nervous system.
Moffett JR; Arun P; Ariyannur PS; Garbern JY; Jacobowitz DM; Namboodiri AM
Glia; 2011 Oct; 59(10):1414-34. PubMed ID: 21598311
[TBL] [Abstract][Full Text] [Related]
22. Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy.
Hull VL; Wang Y; McDonough J; Zhu M; Burns T; Al Ramel N; Dehghani A; Guo F; Pleasure D
Ann Clin Transl Neurol; 2024 Apr; 11(4):1059-1062. PubMed ID: 38282243
[TBL] [Abstract][Full Text] [Related]
23. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms.
Baslow MH; Resnik TR
J Mol Neurosci; 1997 Oct; 9(2):109-25. PubMed ID: 9407392
[TBL] [Abstract][Full Text] [Related]
24. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
Baslow MH; Guilfoyle DN
Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678
[TBL] [Abstract][Full Text] [Related]
25. Developmental increase of aspartoacylase in oligodendrocytes parallels CNS myelination.
Kirmani BF; Jacobowitz DM; Namboodiri MA
Brain Res Dev Brain Res; 2003 Jan; 140(1):105-15. PubMed ID: 12524181
[TBL] [Abstract][Full Text] [Related]
26. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats.
Baslow MH; Kitada K; Suckow RF; Hungund BL; Serikawa T
Neurochem Res; 2002 May; 27(5):403-6. PubMed ID: 12064356
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical localization of aspartoacylase in the rat central nervous system.
Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM
J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127
[TBL] [Abstract][Full Text] [Related]
28. Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Tsen AR; Long PM; Driscoll HE; Davies MT; Teasdale BA; Penar PL; Pendlebury WW; Spees JL; Lawler SE; Viapiano MS; Jaworski DM
Int J Cancer; 2014 Mar; 134(6):1300-10. PubMed ID: 23996800
[TBL] [Abstract][Full Text] [Related]
29. Canavan disease: a white matter disorder.
Kumar S; Mattan NS; de Vellis J
Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up after gene therapy for canavan disease.
Leone P; Shera D; McPhee SW; Francis JS; Kolodny EH; Bilaniuk LT; Wang DJ; Assadi M; Goldfarb O; Goldman HW; Freese A; Young D; During MJ; Samulski RJ; Janson CG
Sci Transl Med; 2012 Dec; 4(165):165ra163. PubMed ID: 23253610
[TBL] [Abstract][Full Text] [Related]
31. Redirecting
Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G
JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442
[TBL] [Abstract][Full Text] [Related]
32. Renewal of oligodendrocyte lineage reverses dysmyelination and CNS neurodegeneration through corrected N-acetylaspartate metabolism.
Lotun A; Li D; Xu H; Su Q; Tuncer S; Sanmiguel J; Mooney M; Baer CE; Ulbrich R; Eyles SJ; Strittmatter L; Hayward LJ; Gessler DJ; Gao G
Prog Neurobiol; 2023 Jul; 226():102460. PubMed ID: 37149081
[TBL] [Abstract][Full Text] [Related]
33. Myelin lesion in the aspartoacylase (Aspa) knockout rat, an animal model for Canavan disease.
Takeda S; Hoshiai R; Tanaka M; Izawa T; Yamate J; Kuramoto T; Kuwamura M
Exp Anim; 2024 Mar; ():. PubMed ID: 38538326
[TBL] [Abstract][Full Text] [Related]
34. Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease.
Francis JS; Markov V; Leone P
J Inherit Metab Dis; 2014 May; 37(3):369-81. PubMed ID: 24288037
[TBL] [Abstract][Full Text] [Related]
35. Involvement of aspartoacylase in tremor expression in rats.
Nishitani A; Tanaka M; Shimizu S; Kunisawa N; Yokoe M; Yoshida Y; Suzuki T; Sakuma T; Yamamoto T; Kuwamura M; Takenaka S; Ohno Y; Kuramoto T
Exp Anim; 2016 Jul; 65(3):293-301. PubMed ID: 27026062
[TBL] [Abstract][Full Text] [Related]
36. Effects of ethanol and of alcohol dehydrogenase inhibitors on the reduction of N-acetylaspartate levels of brain in mice in vivo: a search for substances that may have therapeutic value in the treatment of Canavan disease.
Baslow MH; Suckow RF; Hungund BL
J Inherit Metab Dis; 2000 Nov; 23(7):684-92. PubMed ID: 11117430
[TBL] [Abstract][Full Text] [Related]
37. Acetate supplementation induces growth arrest of NG2/PDGFRα-positive oligodendroglioma-derived tumor-initiating cells.
Long PM; Tighe SW; Driscoll HE; Moffett JR; Namboodiri AM; Viapiano MS; Lawler SE; Jaworski DM
PLoS One; 2013; 8(11):e80714. PubMed ID: 24278309
[TBL] [Abstract][Full Text] [Related]
38. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
[TBL] [Abstract][Full Text] [Related]
39. Canavan disease: a monogenic trait with complex genomic interaction.
Surendran S; Michals-Matalon K; Quast MJ; Tyring SK; Wei J; Ezell EL; Matalon R
Mol Genet Metab; 2003; 80(1-2):74-80. PubMed ID: 14567959
[TBL] [Abstract][Full Text] [Related]
40. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]